Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
47°
Light Rain
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Passage Bio Inc
(NQ:
PASG
)
0.6294
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Passage Bio Inc
< Previous
1
2
Next >
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
October 24, 2024
From
Passage Bio
Via
GlobeNewswire
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference
September 23, 2024
From
Passage Bio
Via
GlobeNewswire
Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)
September 16, 2024
From
Passage Bio
Via
GlobeNewswire
Passage Bio Welcomes Tom Kassberg to Board of Directors
September 10, 2024
From
Passage Bio
Via
GlobeNewswire
Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
August 30, 2024
From
Passage Bio
Via
GlobeNewswire
Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
August 08, 2024
From
Passage Bio
Via
GlobeNewswire
Passage Bio to Participate in Upcoming Investor Conferences
August 06, 2024
From
Passage Bio
Via
GlobeNewswire
Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
August 01, 2024
From
Passage Bio
Via
GlobeNewswire
Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients
July 16, 2024
From
Passage Bio
Via
GlobeNewswire
Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From
Passage Bio
Via
GlobeNewswire
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
May 14, 2024
From
Passage Bio
Via
GlobeNewswire
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
April 22, 2024
From
Passage Bio
Via
GlobeNewswire
Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights
March 04, 2024
From
Passage Bio
Via
GlobeNewswire
Passage Bio to Participate in Upcoming Investor Conferences
February 27, 2024
From
Passage Bio
Via
GlobeNewswire
Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 31, 2024
From
Passage Bio
Via
GlobeNewswire
Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities
December 20, 2023
From
Passage Bio
Via
GlobeNewswire
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
November 17, 2023
From
Passage Bio
Via
GlobeNewswire
Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
November 13, 2023
From
Passage Bio
Via
GlobeNewswire
Passage Bio to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference
October 30, 2023
From
Passage Bio
Via
GlobeNewswire
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 20, 2023
From
Passage Bio
Via
GlobeNewswire
Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines Conference
September 25, 2023
From
Passage Bio
Via
GlobeNewswire
Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights
August 07, 2023
From
Passage Bio
Via
GlobeNewswire
Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study
August 07, 2023
From
Passage Bio
Via
GlobeNewswire
Passage Bio to Participate in Upcoming Investor Conferences
August 01, 2023
From
Passage Bio
Via
GlobeNewswire
Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors
July 31, 2023
From
Passage Bio
Via
GlobeNewswire
Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference
June 05, 2023
From
Passage Bio
Via
GlobeNewswire
Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights
May 11, 2023
From
Passage Bio
Via
GlobeNewswire
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 21, 2023
From
Passage Bio
Via
GlobeNewswire
Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
April 17, 2023
From
Passage Bio
Via
GlobeNewswire
Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days
March 27, 2023
From
Passage Bio
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.